Statements (40)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2020
gptkb:European_Union gptkb:United_States |
| gptkbp:brand |
Jyseleca
|
| gptkbp:casnumber |
1207450-98-2
|
| gptkbp:chemical_formula |
C17 H19 N5 O
|
| gptkbp:clinical_trial |
Phase 3
NCT02914561 NCT02914574 NCT02914600 NCT02914613 NCT02914626 |
| gptkbp:developed_by |
gptkb:Gilead_Sciences
|
| https://www.w3.org/2000/01/rdf-schema#label |
Filgotinib
|
| gptkbp:indication |
gptkb:Crohn's_disease
gptkb:ulcerative_colitis |
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Brazil gptkb:Canada gptkb:Japan gptkb:Mexico gptkb:New_Zealand gptkb:Singapore gptkb:South_Korea gptkb:Switzerland gptkb:United_Kingdom |
| gptkbp:mechanism_of_action |
Janus kinase inhibitor
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
headache nausea infections increased liver enzymes |
| gptkbp:targets |
gptkb:JAK1
|
| gptkbp:used_for |
gptkb:rheumatoid_arthritis
|
| gptkbp:bfsParent |
gptkb:Galapagos_NV
gptkb:EMD_Serono |
| gptkbp:bfsLayer |
5
|